SHANGHAI, China, April 25, 2019 / B3C newswire / -- For second year in a row, Shuwen Biotech was invited to present at the largest annual Companion Diagnostics (CDx) conference in China. This year’s conference saw participation from over 200 attendees representing a variety of leading diagnostics and pharmaceutical players in the rapidly growing CDx space. Shuwen’s CEO and Chairman, Jay Z. Zhang, presented an overview of the history and development of companion diagnostics, the current state of biomarker discovery in the biopharma industry, and future directions, which was received warmly by the audience. Shuwen’s experience in developing some of the earliest PD-L1 and other novel target CDx kits for Chinese biopharma manufacturers and its biomarker testing capabilities in its CAP-accredited central lab were also highlighted in the presentation.
For high resolution please click the image.
“We see a rapidly growing market for companion diagnostics from HCPs, patients, industry and regulatory bodies” said Shuwen’s CEO and Chairman, Jay Z. Zhang. “A major bottleneck to address this need has been the discovery and development of clinically relevant biomarkers and this is why Shuwen is devoting a large portion of its resources to this critical need”.
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen has established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.
Published by B3C newswire and shared through Newronic®